Trials / Unknown
UnknownNCT02317965
Non-Invasive Screening for Fetal Aneuploidy
A Prospective Clinical Study to Evaluate a Novel Non-invasive Prenatal Screening Method for Characterizing Fetal Whole Chromosome Aberrations and Other Major Defects and Deletions Found in the Maternal Blood.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 340 (estimated)
- Sponsor
- Progenity, Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 54 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to detect whole chromosome abnormalities in maternal blood.
Detailed description
The purpose of this study is to detect whole chromosome abnormalities on all chromosomes 13, 16, 18, 21, X and Y, in the fetus through analysis of cell free and compound sample DNA (cf DNA and cs DNA, respectively) in maternal blood. In addition, major deletions and duplications in chromosomes 1, 4, 5, and 22 will be detected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Maternal Blood Draw | Maternal Blood Draw |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2018-11-01
- Completion
- 2018-11-01
- First posted
- 2014-12-17
- Last updated
- 2018-08-28
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02317965. Inclusion in this directory is not an endorsement.